An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
Alan A Martin,1 Daniel Parks2 1Department of Value Evidence Analytics, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Department of Value Evidence Analytics, GlaxoSmithKline, Collegeville, PA, USA Abstract: No head-to-head comparisons exist between once-weekly (QW) glucagon-like peptide-1 receptor agoni...
Main Authors: | Martin AA, Parks D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-05-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Subjects: | |
Online Access: | https://www.dovepress.com/an-indirect-comparison-of-hba1c-treatment-effect-with-albiglutide-and--peer-reviewed-article-DMSO |
Similar Items
-
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Seewoodhary J, et al.
Published: (2010-05-01) -
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017-03-01) -
Jahreslese: Juristische Bücher 2011
by: Alexandra Kemmerer -
Rezension: Das Buch der verlorenen Bücher
by: Sophie Emilia Seidler
Published: (2018-03-01) -
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)